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Abstract
Introduction: Papillary thyroid cancer (PTC) shows familial occurrence, and some susceptibility single nucleotide polymorphisms (SNPs) 
have been identified in FOXE1 and near the NKX2-1 locus. The aim of our study was to analyse the association of PTC risk with SNPs in 
FOXE1 (rs965513, rs1867277, rs1443434) and near the NKX2-1 locus (rs944289) in a Polish population, and, in the second step, the interac-
tion between SNPs and patient-related factors (age at diagnosis and gender). 
Material and methods: A total of 2243 DNA samples from PTC patients and 1160 controls were included in the study. The SNP analysis 
was performed with the allelic discrimination technique.
Results: There were significant associations of all SNPs with PTC (rs965513 odds ratio [OR] = 1.72, p = 8 × 10-7; rs1867277 OR = 1.59, 
p = 1 × 10-6; rs1443434 OR = 1.53, p = 1 × 10-5; rs944289 OR = 1.52, p = 4 × 10-5). Logistic regression analysis revealed an increased PTC 
risk in the interaction of rs944289 with age at diagnosis (OR = 1.01 per year, p = 6 × 10-4) and a decreased PTC risk in the interaction of 
male gender with the GGT FOXE1 protective haplotype (OR = 0.69, p = 0.01). 
Conclusions: The association between PTC and all analysed SNPs was confirmed. It was also shown that patient-related factors modify 
the predisposition to PTC by increasing the risk for rs944289 per year of age, and by enhancing the protective effect of the FOXE1 GGT 
haplotype in men.  (Endokrynol Pol 2017; 68 (3): 283–289)
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Streszczenie
Wstęp: Brodawkowaty rak tarczycy należy do grupy nowotworów litych, w których uwarunkowanie genetyczne ogrywa istotną rolę. 
Geny odpowiedzialne za predyspozycje do raka brodawkowatego nie są dobrze znane, choć polimorfizmy rs965513 i rs944289 obecnie są 
uznanymi czynnikami ryzyka. Celem pracy była analiza związku polimorfizmów znajdujących się w 9q22 w locus genu FOXE1 (rs965513, 
rs1867277, rs1443434) oraz w 14q13 w pobliżu genu NKX2-1 (rs944289) z rakiem brodawkowatym tarczycy oraz ocena wpływu czynników 
zależnych od pacjenta (wieku zachorowania i płci).
Materiał i metody. Materiał obejmował 2243 próbek DNA izolowanych z limfocytów krwi obwodowej pacjentów z rakiem brodawkowatym 
i 1160 próbek DNA pochodzących od osób zdrowych, stanowiących grupę kontrolną (liczba analizowanych próbek różniła się w zależności 
od polimorfizmu). Badania wykonano w aparacie 7900HT Fast Real-Time PCR System firmy Applied Biosystems techniką dyskryminacji alleli. 
Wyniki. Znamienny związek z rakiem brodawkowatym wykazywały wszystkie analizowane polimorfizmy (dla rs965513 wartość OR 
wynosiła 1,72, p = 8 × 10-7; dla rs1867277 OR = 1,58, p = 1 × 10-6; dla rs1443434 OR = 1,53, p = 1 × 10-5; rs944289 OR = 1,52, p = 4 × 10-5). 
Analiza regresji logistycznej wykazała wzrost ryzyka raka brodawkowatego wraz z wiekiem dla polimorfizmu rs944289 (OR = 1.01 na 
rok, p = 6 × 10-4) oraz obniżenie ryzyka zachorowania dla haplotypu GGT genu FOXE1 u mężczyzn (OR = 0,69, p = 0,01).
Wnioski. Potwierdzony został związek badanych polimorfizmów z rakiem brodawkowatym tarczycy w populacji polskiej. Wykazano modyfi-
kujący wpływ wieku zachorowania i płci męskiej na ryzyko zachorowania uwarunkowane genetycznie. (Endokrynol Pol 2017; 68 (3): 283–289)
Słowa kluczowe: polimorfizm; rak brodawkowaty tarczycy; wiek zachorowania; płeć
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Introduction
Papillary thyroid cancer (PTC) is the most frequently 
diagnosed differentiated thyroid cancer (DTC) [1, 2]. 
Genetic predisposition to PTC is the highest of all can-
cers not displaying Mendelian inheritance [3–6]. This 
predisposition is expected to be multigenetic, with in-
teractions among genes and environmental factors de-
termining individual susceptibility [2, 4]; however, the 
genes responsible for PTC are poorly known. To date, 
genetic studies have identified some single nucleotide 
polymorphisms (SNPs) associated with DTCs or PTC, 
although only some of them have been validated [1, 7]. 
In 2009 Gudmundsson et al. identified SNPs associated 
with PTC: rs965513, located upstream of the FOXE1 
gene on chromosome 9q22.33; and rs944289, located up-
stream of the NKX-2 gene on chromosome 14q13.3 [5]. 
At the same time, Landa et al. demonstrated an asso-
ciation between PTC and another SNP located in the 
5-untranslated region of the FOXE1 — rs1867277 [4]. 
However, to date, only a few studies have been per-
formed to assess the association of these SNPs with 
some clinical features of PTC [5, 8, 9]. To our knowledge, 
no study has analysed the mutual interactions between 
identified SNPs and their association with patient- 
-related factors, like gender and age at PTC diagnosis. 
In the present study, we first analysed the associa-
tion of SNPs in the FOXE1 locus (rs965513, rs1867277, 
rs1443434) and near the NKX2-1 gene (rs944289) with 
PTC. Next, we evaluated the interactions between 
these SNPs and their associations with gender and age 
at PTC diagnosis.
Material and methods
Samples and subjects 
A total of 2243 DNA samples derived from PTC patients 
and 1160 samples from controls were analysed. All 
subjects were Caucasians of Polish origin. There were 
1925 (85.8%) women in the PTC group and 949 (81.8%) 
women in the control group. The median age at diag-
nosis of PTC was 48 years (first–third quartile: 37–57 
years). The median age for the control group was 45 
years (first–third quartile: 33–54 years). The number of 
samples analysed differed depending on the SNP and 
DNA availability (Table I). Only samples with all SNPs 
evaluated were included in the linkage disequilibrium 
(LD), haplotype frequency, and logistic regression 
analyses (Table II, III, IV, and VI, respectively).
PTC cases were recruited among thyroid cancer pa-
tients from all over Poland, who were referred for treat-
ment to the Maria Skłodowska-Curie Memorial Cancer 
Centre and Institute of Oncology, Gliwice Branch. Data 
on thyroid cancer histopathology, patient gender, and 
age at diagnosis were extracted from medical records. 
Control subjects were recruited among consenting 
volunteers (from the population in general, from 
workers of the Institute of Oncology, and the persons 
accompanying the patients attending the Institute, not 
related to the patients) and were derived from the same 
populations as the cases. In all control subjects, thyroid 
cancer was excluded by anamnesis and thyroid ultra-
sound. The study was performed with approval from 
the Local Bioethics Committee, and written, informed 
consent was obtained from all participants.
DNA extraction and SNP analysis
DNA was isolated from the whole blood. Two main 
DNA extraction methods were used, i.e., the salting-out 
method and the anion exchange membrane column 
separation method (Genomic Maxi AX Blood; A&A 
Biotechnology, Gdynia, Poland), performed according 
to the manufacturer ’s protocols. Initial screening of 
DNA purity was determined based on evaluation of 
the optical density ratio at 260/280 nm. 
The SNP analysis with the allelic discrimination 
technique was performed on 384-well plates (Applied 
Biosystems, Foster City, CA, USA) using the 7900HT Fast 
Real-Time PCR System (Applied Biosystems, Foster City, 
CA, USA). Reactions were performed in a final volume 
5.1 μl per sample, containing 0.125 μl of 40X TaqMan® 
SNP Genotyping Assay (Applied Biosystems, Foster 
City, CA, USA), 2.5 μl of 2X TaqMan Genotyping Master 
Mix (Applied Biosystems, Foster City, CA, USA), and 
2.5 μl of DNA (at concentrations of 3 ng/μl). 
Statistical analysis
STATISTICA 6 software was used to evaluate the 
genotypes frequency. The odds ratios (ORs) were cal-
culated with their 95% confidence intervals (CI). The 
deviation from Hardy-Weinberg equilibrium for each 
polymorphism was verified. Due to multiple testing, 
the Bonferroni correction was applied to p-values 
resulting from χ2 tests. Haplotype frequencies were 
estimated with the use of the EM algorithm. Logistic 
regression analysis was performed to model the effects 
of analysed SNPs and FOXE1 haplotypes, corrected for 
age at diagnosis and gender. For the logistic regression, 
the Akaike’s Information Criterion-corrected (AICc) 
value was used to evaluate models. A p-value less 
than 0.05 was considered to be statistically significant.
Results 
Association of SNPs with risk of PTC
All analysed SPNs were in Hardy-Weinberg equilibrium 
both in the case and control groups. The genotype 
distributions, allele frequencies, and ORs for all SNPs 
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are presented in Table 1. A significant association for all 
analysed SNPs was observed regarding all models of 
inheritance: genotypic, allelic, dominant, and recessive 
(data not shown). Only OR values for the dominant 
model are included in Table I: 1.72, 1.59, 1.53, 1.52 for 
rs965513, rs1867277, rs1443434, and rs944289, respec-
tively; all of them significant after Bonferroni correction. 
SNPs located in the FOXE1 locus (rs965513, 
rs1867277, rs1443434) were in LD (pairwise D’ ranged 
from 0.5371 to 0.9971 with p values < 10-6) (Table II). 
AAG FOXE1 haplotype was more frequent in PTC cases 
than in controls (40.5% vs. 32.5%), and its presence 
was significantly associated with PTC risk (OR= 1.42, 
p = 1.1 × 10-5) (Table III). By contrast, there was a lower 
frequency of GGT haplotype in PTC patients than in 
controls (43.3% versus 53.7%), and this haplotype was 
significantly associated with a reduced risk of PTC (OR 
= 0.66, p = 8 × 10-8) (Table IV).
Table I. Genotype distribution of analysed SNP among PTC patients and controls
Tabela I. Rozkład genotypów badanych polimorfizmów w grupie chorych z rakiem brodawkowatym i w grupie kontrolnej
Sam-
ple
Median 
Age  
(Q1–Q3)
Females 
(%)
Males 
(%)
N Genotype Allele 
frequency
OR  
(95% CI)
p-value Bonferroni-
corrected 
p-value 
rs965513*
risk allele: A
AA (%) AG (%) GG 
(%)
A G
PTC 47  
(37–56)
717 
(86.1)
116 
(13.9)
833 196 (23.5) 406 (48.7) 231 
(27.7)
0.48 0.52 1.72 
(1.40–2.11)
2 × 10-7 8 × 10-7
Con-
trols
44  
(33–54)
699 
(82.7)
146 
(17.3)
845 125 (14.8) 384 (45.4) 336 
(39.8)
0.38 0.62
rs1867277*
risk allele: A
AA (%) AG (%) GG (%) A G
PTC 48  
(37–57)
1481 
(85.9)
243 
(14.1)
1724 405 (23.5) 879 (51.0) 440 
(25.5)
0.49 0.51 1.59 
(1.33–1.89)
3 × 10-7 1 × 10-6
Con-
trols
44  
(33–54)
721 
(83.0)
148 
(17.0)
869 158 (18.2) 405 (46.6) 306 
(35.2)
0.41 0.59
rs1443434* 
risk allele: G
GG (%) GT (%) TT (%) G T
PTC 48  
(37–57)
1523 
(85.6)
256 
(14.4)
1779 413 (23.2) 909 (51.1) 457 
(25.7)
0.49 0.51 1.53 
(1.28–1.84)
3 × 10-6 1 × 10-5
Con-
trols
44  
(33.5–54)
651 
(82.6)
137 
(17.4)
788 145 (18.4) 370 (47.0) 273 
(34.6)
0.42 0.58
rs944289* 
risk allele: T
TT (%) TC (%) CC (%) T C
PTC 48  
(37–57)
1925 
(85.8)
318 
(14.2)
2243 877 (39.1) 1049 
(46.8)
317 
(14.1)
0.63 0.37 1.52
(1.26–1.83)
1 × 10-5 4 × 10-5
Con-
trols
45  
(33–54)
949 
(81.8)
211 
(18.2)
1160 364 (31.4) 564 
(48.6)
232 
(20.0)
0.56 0.44
Table II. Linkage disequilibrium for SNPs located in the FOXE1 locus
Tabela II. Analiza nierównowagi sprzężeń dla polimorfizmów zlokalizowanych w locus genu FOXE1
PTC 
N = 663
Controls 
N = 590
D′ χ2 p-value D′ χ2 p-value
rs965513:G & rs1867277:G 0.5371 771.3 < 10-6 0.7668 1456.5 < 10-6
rs965513:G & rs1443434:T 0.7889 767.8 < 10-6 0.7877 1523.6 < 10-6
rs1867277:G & rs1443434:T 0.9971 1431.8 < 10-6 0.9692 2571.6 < 10-6
D′ — normalised coefficient of linkage disequilibrium; χ2 — the value of chi-square statistic; SNP — single nucleotide polymorphism; PTC — papillary thyroid 
carcinoma
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Table III. Haplotype frequency of SNPs located in the FOXE1 locus
Tabela III. Częstość haplotypów polimorfizmów zlokalizowanych w locus genu FOXE1
SNP (FOXE1 locus) Haplotype frequency
rs965513 allele rs1867277 allele rs1443434 allele PTC 
N = 663
Controls 
N = 718
G G T 0.433026 43.3% 0.536929 53.7%
A A G 0.405090 40.5% 0.325230 32.5%
G A G 0.071972 7.2% 0.087027 8.7%
A G T 0.053840 5.4% 0.050119 5.0%
A A T 0.002322 0.2% 0.000696 0.1%
G A T 0.013075 1.3%
G G G 0.005306 0.5%
A G G 0.015370 1.5%
SNP — single nucleotide polymorphism; PTC — papillary thyroid carcinoma
Table IV. OR values for the most frequent FOXE1 SNP haplotypes
Tabela IV. Wartości OR dla najczęściej występujących haplotypów polimorfizmów genu FOXE1
rs965513 rs1867277 rs1443434 N OR (95% CI) p-value
Risk haplotype PTC A A G 544/1326 (41%) 1.42 (1.21–1.65) 1.1 × 10-5
Controls A A G 473/1436 (33%)
Protective haplotype PTC G G T 581/1326 (43%) 0.66 (0.57–0.77) 8.0 × 10-8
Controls G G T 777/1436 (54%)
PTC — papillary thyroid carcinoma; OR — odds ratio; CI — confidence interval; SNP — single nucleotide polymorphism 
Association of SNPs with age at diagnosis  
and gender
The PTC patients were divided into two subgroups with 
the reference to the age at diagnosis: ≤ 45 years, and 
> 45 years. (Table V).  Differences were observed only 
for rs965513, but they were not significant after Bonfer-
roni correction. We did not observe any difference in 
genotype distribution between women and men in the 
univariate analysis (data not shown).
Logistic regression
In the first step of the analysis, evaluation of individual 
effects of age and gender was performed - both of them 
were significantly associated with PTC risk (p = 0.0032 
and 0.0375; AICc = 1907.5 and 1911.9, respectively). 
Next, models of inheritance were evaluated. For all 
analysed SNPs and FOXE1 locus haplotypes, the addi-
tive model emerged with the lowest AICc value. Finally, 
based on the AICc, rs1867277, rs944289, the GGT pro-
tective haplotype, age at diagnosis, and gender were 
included into the final regression analysis (Table VI), 
which showed an increased risk of PTC for rs944289 
(OR = 2.65, p = 1.47 × 10-6) and a decreased risk for the 
GGT haplotype (OR = 0.54, p = 3 × 10-4). Moreover, 
analysis of interactions revealed an enhanced risk for 
rs944289 per year of age (OR = 1.014, p = 6 × 10-4) and 
an enhanced protective effect of the GGT haplotype in 
men (OR = 0.699, p = 0.012). 
Discussion
We observed the association of the rs965513, rs1867277, 
rs1443434, and rs944289 SNPs with PTC, and two of 
them (rs1867277 and rs1443434) have not yet been 
analysed in a Polish population. The association of 
rs1867277 with PTC was first described by Landa et al., 
based on a case-control study [4], while rs1443434 b was 
first described by Gudmundsson et al. in a GWAS [5] 
— the results were similar to those obtained in our 
study. The association of rs965513 and rs944289 with 
PTC was analysed by Liyanarachchi et al. in cohorts 
from Poland and the United States [2], with results that 
are in accordance with our study. 
The association of rs965513, rs1867277, rs944289, 
and rs1443434 with PTC has been confirmed in dif-
ferent populations in recent years [8–17]. Moreover, 
four meta-analyses concerning the roles of rs965513, 
rs1867277, and rs944289 in PTC have been published: 
the association of rs965513 has been confirmed among 
both Caucasians and Asians, rs1867277 SNP was ana-
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lysed and confirmed in Caucasians [18–20], whereas 
rs944289 was associated with PTC in Asians, Europeans, 
and Americans [21] . 
The SNPs rs1867277 and rs965513 in the FOXE1 lo-
cus are in moderate pairwise LD in Europeans [12, 13]; 
however, these two SNPs were found to be more 
strongly correlated in a Belarusian population  [17]. LD 
between rs965513 and rs1867277 is significantly weaker 
in populations of African or Asian ancestry [20], which 
is not surprising, since the LD block structure may be 
Table V. Associations of analysed polymorphisms with age at PTC diagnosis
Tabela V. Związek badanych polimorfizmów z wiekiem diagnozy raka brodawkowatego
Age group 
(years)
N Genotype OR (95% CI) p-value Bonferroni- 
corrected p-value
rs965513 
risk allele: A
AA (%) AG (%) GG (%)
≤ 45 383 100 (26.1) 192 (50.1) 91 (23.8) 1.45 (1.06–1.99) 0.018 0.072
> 45 450 96 (21.3) 214 (47.6) 140 (31.1)
rs1867277 
risk allele: A
AA (%) AG (%) GG (%)
≤ 45 766 158 (20.6) 415 (54.2) 193 (25.2) 1.03 (0.83–1.28) 0.78 ns
> 45 958 247 (25.8) 464 (48.4) 247 (25.8)
rs1443434 
risk allele: G
GG (%) GT (%) TT (%)
≤ 45 790 163 (20.6) 423 (53.6) 204 (25.8) 0.99 (0.80–1.22) 0.91 ns
> 45 989 250 (25.3) 486 (49.1) 253 (25.6)
rs944289 
risk allele: T
TT (%) TC (%) CC (%)
≤ 45 995 389 (39.1) 470 (47.2) 136 (13.7) 1.07 (0.84–1.36) 0.57 ns
> 45 1248 488 (39.1) 579 (46.4) 181 (14.5)
ns — not significant; PTC — papillary thyroid carcinoma; OR — odds ratio for dominant model of inheritance; CI — confidence interval
Table VI. Logistic regression analysis
Tabela VI. Analiza regresji logistycznej
Coefficients 
Estimate
Standard 
Error
OR (95% CI) p-value
Subjects: 663 PTC cases, 718 controls
Main effects
Additive, rs1867277 –0.26438 0.17051 0.7677 (0.5496–1.0723) 0.121015
Additive, rs944289 0.97571 0.20262 2.6532 (1.7835–3.9463) 1.47 × 10-6
Additive, protective haplotype GGT –0.62066 0.17172 0.5376 (0.3840–0.7527 0.000301
Interactions
Age (per year): rs944289 0.01367 0.00399 1.0138 (1.0059–1.0217) 0.000610
Gender (male): additive, protective haplotype GGT –0.35705 0.14209 0.6997 (0.5296–0.9245) 0.011979
AICc 1856.16
Residual deviance 1844.1
AICc — Akaike’s Information Criteria-corrected; OR — odds ratio; CI — confidence interval
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different in individuals of different ancestry [22]. In our 
study we observed LD between rs965513, rs1867277, 
and rs1443434; however, that between rs1867277 and 
rs1443434 was the strongest. Our analysis of rs965513/ 
/rs1867277/rs1443434 FOXE1 haplotypes showed an 
increased risk of PTC for the AAG haplotype and a re-
duced risk for the GGT haplotype. Similar results were 
obtained by Jones et al. [13], who showed that carriers of 
haplotypes consisting of both risk alleles of rs965513 and 
rs1867277 in a population from the United Kingdom 
had the highest risk of developing thyroid cancer [13]. 
A significant association also was observed for a haplotype 
in 9q22 consisting of a FOXE1 polymorphism: rs965513/
rs10759944/rs1867277 in thyroid cancer families [14]. 
In our study, some differences in the genotype dis-
tributions of rs965513 were observed between younger 
(diagnosed at ≤ 45 years of age) and older (diagnosed at 
> 45 years of age) patients, although these differences 
were not significant after Bonferroni correction. We 
did not observe differences in genotype distribution 
between women and men in the univariate analysis 
(data not shown). To integrate the results concern-
ing the genotype distribution of rs965513, rs1867277, 
rs1443434, and rs944289 and their association with 
patient-related factors (age at PTC diagnosis and 
gender), we performed a logistic regression analysis. 
Multivariate analysis showed an increased risk of PTC 
for rs944289. A decreased risk was observed for the GGT 
FOXE1 haplotype. Moreover, analysis of interactions 
revealed that risk for rs944289 was increased per year 
of age, and male gender enhanced the protective effect 
of the FOXE1 GGT haplotype. 
Only a few studies have been performed to assess 
the association of the analysed SNPs with PTC clinical 
features [5, 8, 9, 16]. To our knowledge, only one previ-
ous study has evaluated the association between age at 
diagnosis and genetic predisposition, which showed 
a higher frequency of rs965513 A allele carriers among 
PTC patients diagnosed at a younger age [5]. Furthermore, 
only one study has analysed the differences between 
genders, which showed that rs965513 was significantly 
associated with PTC among both women and men [8]. 
The female-to-male ratio of thyroid cancer in Eu-
ropean patients is 2.2 [23], and these sex differences in 
thyroid cancer occurrence have been attributed to differ-
ent endogenous hormone profiles between the genders. 
The protective hormonal effects on the development of 
thyroid cancer in females have been reported, but the 
mechanism remains unclear [24]. However, opposite 
effects were recently observed in rats. Fortunato et al. 
showed that a redox imbalance elicited by oestrogen 
could be involved in the sex differences found in the 
prevalence of thyroid dysfunctions [25]. They observed 
sexual dimorphism in the thyrocyte redox balance, which 
was characterised by increased hydrogen peroxide pro-
duction due to higher NOX4 and Poldip2 gene expres-
sion and weakened enzymatic antioxidant defence in the 
thyroids of adult female rats compared with male rats 
[25]. These findings could lead to the hypothesis that the 
same genetic background has a different effect in males 
and females because of different hormone profiles, which 
would explain the observed enhancement of the protec-
tive effect of the FOXE1 GGT haplotype in men in our 
study. Thus, the presence of the protective haplotype of 
the FOXE1 gene, a thyroid transcription factor gene in-
volved in thyroid peroxidase (TPO) transcription [4, 5], 
might only reveal its protective effect in males and not 
females because of the interacting effects of oestrogens. 
Oestrogens have a general stimulatory effect on thyroid 
function, at least in rats, by increasing iodide uptake and 
TPO activity, as well as H2O2 production [25], which, as 
a reactive oxygen species, causes DNA damage, which 
could lead to the higher frequency of thyroid cancer 
development in women. 
Conclusions
We have confirmed the association of PTC with SNPs 
in the FOXE1 locus on chromosome region 9q22.33 
(rs965513, rs1867277, rs1443434) and one SNP (rs944289) 
near the NKX2-1 gene on chromosome 14q13.3 in a Polish 
population. The importance of FOXE1 haplotypes was 
demonstrated in our population. Logistic regression 
revealed interesting new interactions: the risk of PTC in 
carriers of the rs944289 SNP was increased per year of 
age, and a stronger protective effect of the GGT FOXE1 
haplotype was observed in men. Thus, patient-related 
factors appear to modify the genetic predisposition to 
PTC, at least in our population. To our knowledge, this 
is the first study to evaluate these four SNPs and their 
associations with patient-related factors in the same 
patient set. 
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